Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Floyd F. Petersen acquired 3,200 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was purchased at an average price of $10.35 per share, for a total transaction of $33,120.00. Following the completion of the acquisition, the director now directly owns 41,612 shares in the company, valued at approximately $430,684. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 10.08 on Thursday. Amphastar Pharmaceuticals has a 1-year low of $6.67 and a 1-year high of $11.07. The stock’s 50-day moving average is $9.40 and its 200-day moving average is $9.4. The company’s market cap is $437.5 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.17 EPS for the current fiscal year.

A number of analysts have recently weighed in on AMPH shares. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.